Abstract
Research on malaria vaccines is currently directed primarily towards the development of vaccines that prevent clinical malaria. Malaria elimination, now being considered seriously in some epidemiological situations, requires a different vaccine strategy, since success will depend on killing all parasites in the community in order to stop transmission completely.The feature of the life-cycles of human malarias that presents the greatest challenge to an elimination programme is the persistence of parasites as asymptomatic infections. These are an important source from which transmission to mosquitoes can occur. Consequently, an elimination strategy requires a community-based approach covering all individuals and not just those who are susceptible to clinical malaria.The progress that has been made in development of candidate malaria vaccines is reviewed. It is unlikely that many of these will have the efficacy required for complete elimination of parasites, though they may have an important role to play as part of future integrated control programmes. Vaccines for elimination must have a high level of efficacy in order to stop transmission to mosquitoes. This might be achieved with some pre-erythrocytic stage candidate vaccines or by targeting the sexual stages directly with transmission-blocking vaccines. An expanded malaria vaccine programme with such objectives is now a priority.
Highlights
Development of a malaria vaccine has been difficult
Progress with vaccine development The challenges set to vaccine developers [20] by those who drew up the malaria vaccine road map are first, by 2015, to produce a licensed vaccine that has a protective efficacy of more than 50% against severe disease and death from malaria which lasts longer than one year
Elimination programmes are focused on populations, not individuals, and, optimally, a herd immunity that is sustained and prevents transmission is required
Summary
Development of a malaria vaccine has been difficult. Greatly expanded investment in malaria vaccine research and development in recent years has resulted in the identification of a substantial number of vaccine candidates that are in clinical trials or in the late stages of preclinical development. This does not rule out the use of such vaccines as part of an integrated approach to malaria-elimination, but they are unlikely to induce an anti-parasite immunity of sufficient efficacy to eliminate all parasites It remains to be seen whether attenuated sporozoites, which, in small-scale studies with a demanding and unusable vaccination regime, did give full protection, will be as effective in the trials beginning. There are biological and clinical features of infection that need to be taken into account in designing elimination measures that include vaccines The relevance of this to malaria elimination is that, for many years, there may be a proportion of the population capable of supporting low grade infections from which gametocytes can be derived
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
